PAYER READY CREDENTIALING & COMPLIANCE
ICD-10-CM 2026 · Effective October 1, 2025

ICD-10 D47.3

Billable / Specific HCC v28: 48

Essential (hemorrhagic) thrombocythemia

D47
Block
3
Synonyms
1,297
LCDs
43
Payer Policies
38
Linked CPTs

About ICD-10-CM D47.3

ICD-10-CM code D47.3 represents Essential (hemorrhagic) thrombocythemia. This is a billable/specific code in the Neoplasms chapter (block D47). The 2026 edition of ICD-10-CM D47.3 became effective on October 1, 2025.

Coding Tips for D47.3

Specialist guidance from the PayerReady Medical Coding Team. Specificity warnings, HCC capture rules, sequencing notes.

HCC capture: document with MEAT each year

D47.3 is a CMS-HCC v28 risk-adjustment code (category 48). To count for the patient Risk Adjustment Factor (RAF), document the diagnosis with MEAT language each calendar year: Monitored, Evaluated, Assessed, Treated. A diagnosis on the problem list alone does not satisfy CMS RADV audit standards. Include the diagnosis in the assessment with current status and current treatment plan.

Inclusion Terms / Approximate Synonyms

Clinical terms and conditions classified under D47.3. Per CMS ICD-10-CM Tabular 2026.

  • Essential thrombocytosis
  • Idiopathic hemorrhagic thrombocythemia
  • Primary thrombocytosis

Type 2 Excludes

Not included here, the excluded code is not part of D47.3, but a patient may have both conditions at the same time. Both codes may be coded together when applicable.

  • reactive thrombocytosis (D75.838)
  • secondary thrombocytosis (D75.838)
  • thrombocythemia NOS (D75.839)
  • thrombocytosis NOS (D75.839)

Medicare Advantage HCC Impact

CMS-HCC v28 (current)
Category 48
ESRD-HCC
Category 48
RxHCC (Part D)
Category 48

Capture this diagnosis annually for accurate risk adjustment. Missed HCC captures are the #1 revenue leak in Medicare Advantage risk programs.

Medicare LCD Coverage for D47.3

Local Coverage Determinations (LCDs) from CMS MACs that list D47.3 as a covered diagnosis.

1,297 LCDs

Showing top 10 of 1,297 total . Click a CPT for full coverage scope.

CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81215 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81300 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81351 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81167 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81405 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 0103U →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81201 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81297 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81298 →
CMS LCD: Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
Article ID: 58679, Effective: 2026-02-05 00:00:00, 1346 covered, 0 non-covered
CPT 81299 →

Commercial Payer Coverage

Coverage policies from major commercial payers referencing D47.3.

43 policies

1 Cigna

Flow Cytometry - (0538)
Policy ID: MM_0538

5 Medicare

Oral Anticancer Drugs - Policy Article
Policy ID: ART-52479
Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article
Policy ID: ART-52480
Billing and Coding: Biomarkers for Oncology
Policy ID: ART-52986
Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions
Policy ID: ART-55639
Billing and Coding: Lab: Flow Cytometry
Policy ID: ART-55717

CPT Codes Commonly Billed with D47.3

Procedures frequently paired with this diagnosis based on PayerReady's Dx↔Px linkage data.

38 linkages
  • J0840 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J0850 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • 90371 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • 90375 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1573 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1569 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1459 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1557 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1556 CMS LCD: Billing and Coding: Immune Globulins CMS LCD
  • J1560 CMS LCD: Billing and Coding: Immune Globulins CMS LCD

Convert D47.3 to ICD-9-CM

Per CMS General Equivalence Mappings (GEMs), useful for legacy data review and historical claim analysis.

ICD-10ICD-9Mapping Flags
D47.3 23871 10000

Flags format (5 digits): Approximate · No Map · Combination · Scenario · Choice List. Source: CMS 2017 GEMs (final version).

ICD-10 D47.3, Billing FAQ

Is ICD-10 code D47.3 billable? +

Yes, D47.3 is a billable ICD-10-CM code that can appear as a primary or secondary diagnosis on claims.

What other names or terms map to D47.3? +

ICD-10 D47.3 includes: Essential thrombocytosis; Idiopathic hemorrhagic thrombocythemia; Primary thrombocytosis.

What codes are Type 2 Excludes for D47.3? +

Type 2 Excludes (may be coded together when both conditions exist): reactive thrombocytosis (D75.838); secondary thrombocytosis (D75.838); thrombocythemia NOS (D75.839)

Does D47.3 affect Medicare Advantage HCC risk adjustment? +

Yes. D47.3 maps to CMS-HCC v28 category 48. Capture this diagnosis annually for accurate Medicare Advantage risk score.

What CPT codes are commonly billed with D47.3? +

Procedures frequently paired with D47.3 include: J0840, J0850, 90371, 90375, J1573.

What ICD-9 codes does D47.3 map to? +

Per CMS GEMs, D47.3 maps to ICD-9 codes: 23871. Useful for legacy data review and historical claim analysis.

Get the full PayerReady toolkit

Free access to CPT/ICD-10 lookup, denial appeals, fee comparator, and claim auditing with credentialing enrollment.

Start free →

Run this code through our claim audit tool

Check NCCI bundling, MUE limits, and modifier logic before submission.

Try the auditor →

Did this page help?

Quick signal so we know what to improve.

Thanks!

If you want a code reference page that doesn't exist yet, email coding@payerready.com.

Sorry to hear that.

Tell us what's missing or wrong: coding@payerready.com. We respond within 5 business days.

Reviewed by the PayerReady Medical Coding Team

Verified against the CMS 2026 code set on July 16, 2026.

Powered by 11K CPT · 98K ICD-10 · 860K MPFS rates · 4.5M NCCI edits · 9.5M NPIs. Our data methodology · About our coding team

Every month un-credentialed is revenue you never bill

Sign up free, add your first provider, and watch the pipeline start moving this week.

Ask CredBrain

Answers from your credentialing team's verified knowledge base

Hi, I'm CredBrain. I answer from your credentialing team's verified knowledge base: payer join paths, state rules, timelines, associate billing, and enrollment workflows. If I don't have a verified answer, I'll say so and point you to your team. What would you like to know?

Try asking